Global Health Agencies and Vaccine-Preventable Deaths

Peter Bottomley Excerpts

Thursday 9th May 2024 Westminster Hall

[Sir Gary Streeter (in the Chair)]

Before I turn to the SNP spokesman, can I check whether the Father of the House wishes to speak in the debate?

[Sir Peter Bottomley (Worthing West) (Con)]

I apologise for not having been here on time. I think to make a speech would be wrong; I hope it will be acceptable to intervene on one of the Front-Bench speakers.

[Sir Gary Streeter (in the Chair)]

Thank you very much indeed. Let us turn then to our SNP spokesman.

--- Later in debate ---

[The Deputy Foreign Secretary (Mr Andrew Mitchell)]

It is a great pleasure once again to perform under your benign sway, Sir Gary. I congratulate the hon. Member for Ealing, Southall (Mr Sharma) on his excellent speech, as well as on his work with the APPG and on the Select Committee, alongside the hon. Member for Dundee West (Chris Law). So constructive are the performances that the hon. Member for Ealing, Southall always turns in that the first draft of the speech given to me by officials referred to him as “my hon. Friend”. I would not wish to embarrass him by any suggestion on that score, but he does a great deal of good work, for which we are very grateful. We are also very grateful that the Father of the House is here, which emphasises the importance of the subject and the all-party nature of our concerns.

[Sir Peter Bottomley]

I reflect that it is 45 years since I served on the Select Committee on Overseas Development, before 1979. The point that I would like my right hon. Friend to consider, if not to answer today, is how to go on ensuring that vaccination and immunisation programmes work in times of conflict. I spent this morning with Action Against Hunger looking at United Nations Security Council resolution 2417 of 2018, which concerns conflict and hunger, but the problem of conflict and the hindering of vaccination programmes also needs deep consideration.

[Mr Mitchell]

My hon. Friend makes a good point, which I will answer straightaway. It is worth emphasising that we are getting better at operating in very contested spaces. For example, he will know of the work that Education Cannot Wait is doing in very difficult circumstances, particularly where people have been forced to move or where there has been migration as a result of violence or climate change. On all these things, we are getting better at serving communities in extreme difficulty, but my hon. Friend raises a very interesting point, and if I have anything further to add on that, I will write to him shortly.

I am grateful for the opportunity to highlight the importance of immunisation for global health. I am also grateful to the hon. Member for Dundee West, who raised a number of interesting points, all of which I think I am going to cover, and to the hon. Member for Hornsey and Wood Green (Catherine West), who speaks on these matters for the Opposition, in particular for the comments that she made about GSK. It is worth pointing out that this is an area where a vital part is played not only by the private sector and the pharmaceutical industry, but by philanthropic organisations, many of which are very concerned with the area. There is no doubt that, as Bill Gates always says, vaccinating children is one of the best value for money interventions that can be made, with the widest and deepest effects. The hon. Lady’s points about GSK are very welcome indeed.

The hon. Lady asked me about R&D issues and about higher education, and I will make two points. First, she is absolutely right to emphasise the importance of the R&D budget. She will have noticed that, during a very difficult period in which cuts—sometimes very serious cuts—were made in development spending, the R&D budget has been defended throughout. Indeed, as we have projected forward the draft figures, we have again protected the R&D budget in development, and it will, I think, be rising over the next few years. Like her, I have seen the remarkable work that that budget is doing. In the UK, I recently visited the Jenner Institute and saw the brilliant work that so many are doing there. I agree with the hon. Lady about the importance of R&D.

Secondly, in relation to spreading British higher education skill into Africa, I point out to the hon. Lady the recently announced programme for the Tropical Health and Education Trust, which I launched in London. THET does a huge amount of good work in this respect. We had an excellent programme some 10 years ago, and I am very pleased indeed that we have been able to renew that.

All my colleagues who spoke in the debate shone a spotlight on our lifesaving work with partners, including Gavi, the Vaccine Alliance; the Global Fund to Fight AIDS, Tuberculosis and Malaria; and Unitaid. We see strong support in every part of the House for those lifesaving efforts, and I am very grateful for the contributions of Members here today in that respect.

I will endeavour to respond to all the points raised, but first I want to make a point specifically about Gavi, which I was asked about by the hon. Member for Ealing, Southall. He will, I think, recall that in 2011, when I had the privilege of being the International Development Secretary, we did the Gavi replenishment in London, and there has been a subsequent replenishment since that time. The point that I want to make to him is that that pivotal replenishment in 2011 was very heavily supported. Incidentally, we know that 83% of the British public thought that spending taxpayers’ money on vaccinating children under five in the developing world should be supported; they showed approval for that. I thought that was a very encouraging statistic then, and I have hopes for the upcoming replenishment, on which I wish to assure the hon. Gentleman. I cannot put a figure on the table now, but both I and the Foreign Secretary are very focused on the replenishment, because we know the good that this work does, which the hon. Gentleman so eloquently set out. We will undoubtedly be key supporters of the replenishment when we make our contribution.

I was also asked about the Global Fund. If I may say so, I thought that the hon. Member for Dundee West was a little unfair in criticising the figure. It was the first significant pledge when I returned to the Government in October 2022; we managed to get the system to agree. My right hon. Friend the Chancellor of the Exchequer was very keen on spending the money on the Global Fund, as was the Prime Minister, who emphasised the importance of the work, and £1 billion—a thousand million pounds—of taxpayers’ money is not to be sniffed at. If the hon. Member for Dundee West looks at what Peter Sands, the chief executive of the Global Fund, said at the time and subsequently about Britain’s support, both financial and in many other ways, I am sure that his spirits will be lifted.

In respect of the pandemic accord negotiations, which the hon. Member also mentioned, although I have nothing to say today, I think that they are proceeding well. The British Government have spent a great deal of time on that this week, and I hope that when the announcements are made in due course by Tedros from the WHO, the hon. Gentleman will be pleased and relieved at what we are able to achieve.

Vaccines have saved more than 150 million lives over the last 50 years, including more than 100 million children. That is six lives saved every minute for five decades. I am sure that we can all agree that this is one of humanity’s greatest achievements. The UK’s support for childhood vaccinations around the world has played its part, together with institutions including the World Health Organisation, Gavi, the Global Fund and Unitaid. However, the covid pandemic threatened to undo our hard-won progress, sparking the largest reversal in child vaccination rates in three decades and leading to increased outbreaks and deaths. Although vaccination rates have recovered since, global health is, as with everything, bound up with geopolitics. We stand at a crucial juncture in that respect. In these increasingly challenging times, we can only maintain our progress on global vaccines by uniting forces and standing together to ensure the health of future generations.

Let me be clear: reaching the world’s children with vaccination remains a top priority for Britain, as set out so clearly in our widely endorsed international development White Paper. We are determined to enhance our partnerships with individual countries and strengthen our collaborations with organisations such as Gavi, which will help continue to save countless lives.

The UK has supported Gavi since its inception 24 years ago. By bringing together Governments, private sector foundations, civil society organisations and vaccine manufacturers, it has vaccinated—that is to say, Britain has vaccinated—more than 1 billion children, saving more than 17 million lives. I am glad to say that Britain was one of the six original donors, and it hosted Gavi’s most successful summits, in 2011 and then in 2020, when we committed £1.65 billion over five years. Later that year, at the UN General Assembly, we pledged an additional £548 million to the Gavi COVAX advance market commitment to support lower income countries with covid vaccines.

We are now looking ahead, working closely with Gavi to develop a strong strategy for the next five years. That includes reaching all children with routine immunisations, and better integrating that with primary healthcare services. We want to improve co-ordination with other global health institutions to ensure that programmes are sustainable and, most importantly, led by countries themselves.

We are also looking ahead to the gathering hosted by the French Government, the African Union and Gavi this summer in Paris. President Macron will launch an accelerator mechanism to help African vaccine manufacturers produce vaccines in Africa and become commercially sustainable on a long-term basis. The UK looks forward to announcing the details of our support for that work, demonstrating the importance we place on a united global effort to improve access to vaccines and better prepare for future health emergencies. Those are all things that I have discussed in detail with Akinwumi Adesina, the president of the African Development Bank.

The roll-out of the malaria vaccines, which were referred to, not least by the hon. Member for Hornsey and Wood Green, highlights the role the UK has already played in end-to-end support of innovation vaccines. First, working in collaboration with partners in India, our world-leading scientists helped to develop these game-changing new vaccines, which must be used in combination with bed nets and chemoprotection. Then, supported by UK funding, Gavi, the Global Fund, Unitaid and the World Health Organisation set up pilots to provide the evidence necessary for a wider roll-out, and Britain’s MedAccess, so brilliantly led by Michael Anderson, worked with Gavi to secure the vaccine supply.

The vaccine roll-out will protect more than 6 million children from malaria by the end of next year. This is the first time that Gavi and the Global Fund will be working together on a single disease, and it presents a wonderful opportunity to strengthen their efforts even further. The wider work to prevent and treat diseases such as malaria, HIV and TB is also helping to save countless lives.

Britain was a founding donor to Unitaid 20 years ago, and has contributed more than half a billion pounds over the years. Today, more than 170 million people benefit from health products supported by Unitaid every year, from the latest HIV treatments to next-generation mosquito nets. Two weeks ago, on 24 April, I was delighted to join a parliamentary reception hosted by Unitaid, at which I reiterated Britain’s firm support for it.

Another great example of our investment in cutting-edge research and development is the recent deployment in Nigeria of the innovative MenFive vaccine. That revolutionary new shot is a powerful shield against the five major strains of the bacteria that cause meningitis. The research into MenFive was funded by Britain and developed through a partnership between PATH—a global non-profit organisation—and the Serum Institute of India. The roll-out of 1 million vaccines in northern Nigeria came from Gavi-funded stocks approved by the World Health Organisation last year. MenFive will be rolled out in other countries—Niger is expected to start vaccinating imminently—giving a big boost to our work to end meningitis globally by the end of the decade. That is exactly the kind of scientific innovation that Britian will continue to support, driving further break- throughs that will help to wipe out other preventable diseases.

While we are speaking of the future, let me turn to the matter of replenishments for our partners for the next 12 months, including Gavi, the Global Fund and the World Health Organisation. As I confirmed in my opening remarks, we are considering how and where our funding can have the greatest impact, and we look forward to announcing our contributions at the replenishment events.

I hope I have done justice to the work that Britain has done with our partners, which has saved countless lives. Those collaborations and scientific breakthroughs have enabled us to eradicate smallpox, and—thank goodness —we are on the verge of eradicating polio, which the hon. Member for Ealing, Southall raised. Children around the world are now protected against 19 deadly diseases through routine immunisation via Gavi.

There is, of course, more to do, and we will keep up the momentum. Nobody should die of a preventable illness, and everyone, everywhere should have access to these wonderful innovations. That is how we build a healthier and fairer world for all.